Biotech | April 06, 2026
Enveric Biosciences bags key US patent for mental health drug
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
The protections extend through at least 2035, with the potential for further extensions
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The move strengthens GBL’s clinical-stage presence in the United States
Subscribe To Our Newsletter & Stay Updated
